Tag: Cd20

In clinical studies, rituximab treatment has been shown to cause a rapid and profound depletion of peripheral B-cells within 72 hours. This monoclonal antibody, therefore, is primarily known for its ability to deplete B-cells by targeting a specific protein on their surface.

Ristova, a targeted anticancer and autoimmune treatment, contains the powerful active ingredient rituximab, an anti-CD20 monoclonal antibody. To understand **what is the active ingredient in Ristova**, one must examine how this specialized protein precisely targets and depletes specific B-lymphocytes.